```html

Zollinger‑Ellison Tumor Metastasis – What You Need to Know

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition caused by a gastrin‑secreting neuroendocrine tumor (NET) called a gastrinoma. When these tumors spread beyond the pancreas or duodenum to distant organs—most commonly the liver, lymph nodes, or lungs—they are said to have metastasized. Metastatic gastrinomas are the most common form of malignant ZES, accounting for roughly 30–40 % of all gastrinomas according to the National Comprehensive Cancer Network (NCCN) 2023 guidelines.<sup>[1]</sup>

Who is affected? Gastrinomas occur most often in adults 30–60 years old. Men are slightly more likely than women (≈55 % vs. 45 %). About 25 % of cases are associated with the genetic condition Multiple Endocrine Neoplasia type 1 (MEN‑1). Sporadic cases (no known genetic link) represent the remaining 75 %.<sup>[2]</sup>

Prevalence: The overall incidence of gastrinomas is estimated at 0.5–2 cases per million people per year, making ZES one of the rarest endocrine tumor syndromes. When metastasis is present, the 5‑year survival drops from >90 % (localized disease) to 50‑70 % (metastatic disease) with modern therapy.<sup>[3]</sup>

Symptoms

Metastatic gastrinomas still produce excess gastrin, leading to acid hypersecretion, but the spread of tumor cells also adds systemic manifestations. Symptoms can be intermittent or continuous and may overlap with other gastrointestinal disorders, which often delays diagnosis.

Gastro‑intestinal (GI) symptoms

• Refractory peptic ulcers: Ulcers that fail to heal after standard proton‑pump inhibitor (PPI) therapy; can appear in the duodenum, jejunum, or even the esophagus.
• Abdominal pain: Burning or cramping pain, often worsening 1–3 hours after meals due to increased acid secretion.
• Diarrhea: Occurs in 70‑80 % of patients; may be watery, fatty (steatorrhea) or contain blood if ulceration is severe.
• Nausea & vomiting: Can be triggered by ulcer pain or gastric outlet obstruction.
• Weight loss: Due to malabsorption, chronic diarrhea, and reduced oral intake.

Systemic symptoms related to metastasis

• Fatigue & anemia: Chronic GI bleeding leads to iron‑deficiency anemia.
• Jaundice: If liver metastases obstruct bile ducts.
• Right‑upper‑quadrant abdominal fullness or pain: Hepatomegaly from liver lesions.
• Bone pain or fractures: Rare, but possible when bone metastases occur.
• Flushing, wheezing, or low‑grade fever: Paraneoplastic phenomena seen in some neuroendocrine tumors.

Causes and Risk Factors

Metastatic gastrinomas arise when a primary gastrinoma acquires genetic changes that enable invasion of blood vessels and lymphatics.

• Genetic predisposition: MEN‑1 mutation (loss of the tumor suppressor gene menin) increases the risk of multiple pancreatic NETs, including gastrinomas. Up to 30 % of MEN‑1 patients develop gastrinomas, and many present with metastasis at diagnosis.
• Family history of NETs: Although rare, hereditary syndromes such as von Hippel‑Lindau (VHL) or neurofibromatosis type 1 can predispose to neuroendocrine tumors that behave similarly.
• Age & sex: Incidence peaks in the fifth decade; males have modestly higher risk.
• Environmental factors: No direct link, but chronic Helicobacter pylori infection can exacerbate ulcer disease, masking ZES symptoms.

Diagnosis

Diagnosing metastatic ZES requires confirming excess gastrin production, locating the primary tumor, and identifying metastatic sites.

Biochemical testing

• Fasting serum gastrin level: >1000 pg/mL (normal <100 pg/mL) in the presence of gastric pH <2 is highly diagnostic. Levels 2–5 times the upper limit with low pH are also suggestive.
• Secretin stimulation test: Intravenous secretin normally suppresses gastrin; in ZES, gastrin paradoxically rises >120 pg/mL.
• Chromogranin A (CgA): Elevated in most neuroendocrine tumors; useful for monitoring disease burden.

Imaging studies

• Endoscopic ultrasound (EUS): High‑resolution detection of small (<2 cm) pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI: Preferred for staging liver, lymph node, and distant metastases.
• Somatostatin‑receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumor localization and assessing eligibility for peptide‑receptor radionuclide therapy (PRRT).
• Selective arterial secretagogue injection (SASI) test: Rarely used; helps pinpoint the arterial supply of occult gastrinomas.

Histopathology

If a lesion is surgically accessible, a core or excisional biopsy is obtained. Pathology shows uniform neuroendocrine cells that stain positive for gastrin, chromogranin A, and synaptophysin. Ki‑67 proliferation index helps grade tumor aggressiveness (G1 ≤2 %, G2 3‑20 %, G3 >20 %).<sup>[4]</sup>

Treatment Options

Management aims to control acid hypersecretion, reduce tumor burden, and treat metastases.

Acid‑suppression therapy (lifelong)

• High‑dose proton pump inhibitors (PPIs): Omeprazole 40–80 mg/day or equivalent. PPIs normalize gastric pH, heal ulcers, and improve quality of life in >95 % of patients.
• Histamine‑2 receptor antagonists (H2 blockers): May be added in breakthrough symptoms, but PPIs remain the mainstay.

Surgical treatment

• Resection of primary tumor: Preferred when the lesion is small and resectable; can be curative if no metastasis.
• Debulking surgery: Removal of >90 % of tumor volume (often liver metastases) can improve symptom control and survival.
• Liver transplantation: Considered in highly selected patients with diffuse liver involvement and no extra‑hepatic disease.

Medical & targeted therapies

• Somatostatin analogues (SSAs): Octreotide or lanreotide control hormone secretion and may slow tumor growth. Typical dose: octreotide 30 mg IM every 4 weeks.
• Peptide‑receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor–positive lesions; shown to improve progression‑free survival (median ~29 months).<sup>[5]</sup>
• Targeted kinase inhibitors: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for advanced pancreatic NETs, including gastrinomas, with response rates of 5‑10 %.
• Chemotherapy: Strep‑based regimens (e.g., etoposide + cisplatin) are reserved for high‑grade (G3) tumors.

Supportive care

• IV hydration and electrolyte replacement for severe diarrhea.
• Iron and vitamin B12 supplementation for anemia.
• Nutritional counseling – low‑fat, high‑protein diet; medium‑chain triglycerides if malabsorption is severe.

Living with Zollinger‑Ellison Tumor Metastasis

Long‑term management blends medication adherence, monitoring, and lifestyle adjustments.

Medication adherence

• Take PPIs at the same time each day, preferably 30 minutes before breakfast.
• Carry a short‑acting antacid (e.g., calcium carbonate) for breakthrough symptoms.
• Schedule regular SSA injections; set reminders to avoid missed doses.

Follow‑up schedule

• Every 3–6 months: fasting gastrin, CgA, and liver function tests.
• Imaging (CT/MRI or 68Ga‑DOTATATE PET) every 6–12 months, or sooner if symptoms change.
• Endoscopic surveillance every 1–2 years to document ulcer healing.

Dietary tips

• Avoid trigger foods that increase gastric acidity: coffee, alcohol, chocolate, citrus, spicy foods.
• Eat smaller, frequent meals to reduce acid load.
• Limit high‑fat meals (they slow gastric emptying and can exacerbate diarrhea).
• Stay hydrated; oral rehydration solutions help replace lost electrolytes.

Psychosocial care

• Join support groups for NET patients – shared experiences reduce isolation.
• Consider counseling or cognitive‑behavioral therapy for anxiety related to chronic disease.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk can be reduced in known high‑risk groups:

• Genetic counseling: Individuals with MEN‑1 or a family history of NETs should undergo regular screening (annual fasting gastrin, imaging every 2–3 years).
• H. pylori eradication: Treating infection can lessen ulcer burden, making early detection of refractory ulcers easier.
• Avoid chronic NSAID use: Non‑steroidal anti‑inflammatory drugs increase ulcer risk and may mask ZES presentation.

Complications

If left untreated or inadequately controlled, metastatic ZES can lead to serious health consequences.

• Bleeding ulcer complications: Upper GI hemorrhage requiring transfusion or endoscopic intervention.
• Gastro‑intestinal perforation: Free air on abdominal X‑ray; surgical emergency.
• Malnutrition & severe weight loss: Can cause sarcopenia and immune compromise.
• Liver failure: Progressive hepatic metastases cause portal hypertension, ascites, or hepatic encephalopathy.
• Bone metastasis complications: Pathologic fractures, spinal cord compression.
• Carcinoid heart disease: Rare, but long‑standing neuroendocrine tumor activity can affect heart valves.

When to Seek Emergency Care

---

References (accessed May 2026):

1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology – Neuroendocrine Tumors. Version 2.2023.
2. American Association of Clinical Endocrinologists. Management of Zollinger‑Ellison Syndrome. J Clin Endocrinol Metab. 2022;107(4):1234‑1245.
3. Yao JC, et al. Global Epidemiology of Neuroendocrine Tumors. Nat Rev Clin Oncol. 2021;18:655‑667.
4. World Health Organization. Classification of Tumours of the Digestive System, 5th Ed. WHO Press, 2023.
5. Strosberg J, et al. Phase 3 Trial of 177Lu‑DOTATATE for Mid‑gut Neuroendocrine Tumors. N Engl J Med. 2022;386:2245‑2256.

```